Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
?I don?t think the market is responsive today to putting more and more sales people focused on brands,? Enrique Conterno, president of Lilly Diabetes, said in an interview. ?We start with the patient and think of all the therapies we could have for him? instead of ?trying to force a brand? on both diabetics and physicians, he said.
Earlier this year, Novo Nordisk A/S (NOVOB), the world?s biggest maker of insulin, redirected its U.S. sales force to boost promotion of the diabetes drug Victoza. Soon after, revenue slowed for competing treatments from Merck & Co. (MRK:US) and Bristol-Myers Squibb Co. (BMY:US), forcing them to increase sales efforts for their own medicines.
http://www.businessweek.com/news/20...over-quantity-will-pay-off-in-diabetes-battle
Earlier this year, Novo Nordisk A/S (NOVOB), the world?s biggest maker of insulin, redirected its U.S. sales force to boost promotion of the diabetes drug Victoza. Soon after, revenue slowed for competing treatments from Merck & Co. (MRK:US) and Bristol-Myers Squibb Co. (BMY:US), forcing them to increase sales efforts for their own medicines.
http://www.businessweek.com/news/20...over-quantity-will-pay-off-in-diabetes-battle